10 Pump and Dump Stocks Favored by Hedge Funds

1. Arvinas, Inc. (NASDAQ:ARVN)

Number of Hedge Fund Holders: 32

Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for the treatment of cancer and other diseases. Its proprietary PROTAC® (Proteolysis-Targeting Chimera) technology harnesses the body’s natural protein disposal system to selectively degrade disease-causing proteins. The company’s pipeline includes candidates for metastatic breast cancer, prostate cancer, and neurological disorders. ARVN generates revenue through research collaborations, licensing agreements, and potential future drug commercialization, positioning itself as a leader in the emerging field of targeted protein degradation.

Arvinas, Inc. (NASDAQ:ARVN) is approaching several major milestones, including their first Phase III top-line data results expected later in Q1 2025 and first-in-human data from their PROTAC targeting neurodegenerative disease. The company’s lead program, vepdegestrant (vepdeg), is being developed with Pfizer as a potential best-in-class ER-targeting backbone therapy for breast cancer treatment. In 2025, ARVN plans to initiate two Phase III combination trials – one evaluating vepdeg with Pfizer’s novel CDK4 inhibitor atirmociclib in the first-line setting, and another combining vepdeg with a CDK4/6 inhibitor in the second-line setting.

Arvinas, Inc. (NASDAQ:ARVN)’s neuroscience program made significant progress with ARV-102, their LRRK2 degrader, with first-in-human data to be presented at the AD/PD Conference in April. Additionally, ARVN plans to share preliminary data from their Phase I trial of ARV-393, their BCL6 degrader for non-Hodgkin lymphomas, and expects to file an IND application for their KRAS G12D degrader in 2025. Financially, ARVN maintains a strong position with over $1 billion in cash, cash equivalents, and marketable securities, sufficient to support operations into 2027. The company recorded $263.4 million in revenue for the year compared to $78.5 million in the prior year.

Overall Arvinas, Inc. (NASDAQ:ARVN) ranks first on our list of the 10 pump and dump stocks favored by hedge funds. While we acknowledge the potential of ARVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARVN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks To Buy Now According to Billionaires

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.